Tolerance In Organ Transplantation And Autoimmune Disease By T Cell Immunotoxin
T 细胞免疫毒素对器官移植和自身免疫性疾病的耐受性
基本信息
- 批准号:7594527
- 负责人:
- 金额:$ 113.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adverse effectsAllograftingAntibodiesAntigen PresentationAppearanceAutoimmune DiseasesB-LymphocytesBackBindingBinding SitesBloodBlood GlucoseCD3 AntigensCell TransplantsChronicClinicalClinical ResearchClinical TreatmentCyclosporineCyclosporinsDiabetes MellitusDiphtheria ToxinEpitopesExhibitsGlycosylated HemoglobinGraft SurvivalGusperimusHIVHourHumanImmunizationImmunosuppressionImmunotoxinsInstitutionInsulinInsulin-Dependent Diabetes MellitusIslets of LangerhansIslets of Langerhans TransplantationKidney TransplantationKnowledgeMacaca mulattaMalignant NeoplasmsMediatingMethylprednisoloneModelingMonkeysMonoclonal Antibody HuM291Muromonab-CD3NumbersOrganOrgan TransplantationPhase I Clinical TrialsPichiaProcessProductionProteinsProtocols documentationReagentRecombinant AntibodyRecombinantsReportingResistanceSideSolid NeoplasmSpecificityStreptozocinStructureSurvivorsT-Cell DepletionT-Cell LeukemiaT-LymphocyteTherapeutic immunosuppressionToxinTransplantationViralYeastscell killingcell typechemical conjugatedaydesiregraft versus host disease inductionin vivoisletkillingslymph nodesmutantpreclinical studyresponse
项目摘要
The general aim of this project is to study the effects of immunotoxin induced transient T-cell depletion on the modulation of T cells from immunization responses towards tolerizing responses, and to use this knowledge for the experimental and clinical treatment of T cell driven autoimmune diseases, graft-versus-host disease, and the induction of tolerance to mismatched organ and cell transplants. We previously showed that a 2-3 day course of anti-rhesus CD3 immunotoxin constructed with CRM9, a binding site mutant of diphtheria toxin, depletes lymph node and blood T cells by 99% after a 48 hour lag period. This process was associated with a marked prolongation of survival of mismatched functioning rhesus kidney transplants, 50% over 9 months without further immunosuppressive therapy. Rejections, were preceded by the appearance of anti-graft antibodies (done with S. Knechtle and J. Thomas). To circumvent this adverse T cell mediated B cell response that is apparently initiated during the delay in immunotoxin induced T cell killing, we have added a short course of agents that are believed to block antigen presentation such as deoxyspergualin (DSG). Out of 5 bilaterally rephrectomized recipients long term tolerance was achieved in 3 without further immunosuppresion as judged by a graft survival of 4 years or longer. Congeneic pancreatic islet cell transplants in monkeys suffering from spontaneous insulin dependent diabetes have been shown to reverse diabetes as judged by returning non-fasting blood glucose and glycosylated hemoglobin values to normal in the absence of exogenous insulin. A short course of immunotoxin, methyl prednisolone and cyclosporine provide induction of stable operational tolerance to islets that has lasted over one year in one case. This is the first reported reversal of diabetes using a tolerizing protocol that does not depend on chronic immunosuppression, a process previously shown to compromise transplanted islet function (done with J. Thomas). Streptozotocin induced diabetes in monkeys has been successfully reversed by using anti-T cell immunotoxin in combination with 14 days of DSG and allografted pancreatic islets (done with J. Thomas). Three out of seven are long term tolerant survivors (6-7 years). A recombinant divalent anti-human anti-T cell immunotoxin has been developed that has 20-fold the potency of the previous chemical conjugates. This is expressed in Pichia pastoris. This material has now been produced for a phase I clinical trial in T cell leukemia and an INDA has been filed. In order to aid the production of immunotoxin and other bioactive proteins in Pichia pastoris, new strains have been constructed that exhibit toxin resistance and increased heterologous protein production in the presence of an active unfolded-protein response.
Recently, a recombinant anti-CD3 immunotoxin active against monkey T cells has been developed. This was done in order to facilitate pre-clinical studies in organ transplantation and autoimmune diseases. A side benefit of this study was that it required explorations of different recombinant antibody geometries for optimal activity. A fold-back diabody structure was found to be most optimal toward monkey CD3. Model building studies predicted that this structure should have very high binding activity towards targets that contain homodimeric epitopes rotated by 180 degrees. This prediction was found to be true in the case of a human solid tumor epitope and clinical studies at another institution are planned.
该项目的总体目标是研究免疫毒素诱导的瞬时T细胞耗用对T细胞从免疫反应到耐受反应的调节的影响,并将这一知识用于T细胞驱动的自身免疫性疾病、移植物抗宿主病和诱导对错配器官和细胞移植的耐受的实验和临床治疗。我们之前的研究表明,用白喉毒素结合位点突变体CRM9构建的抗恒河猴CD3免疫毒素2-3天疗程后,在48小时的滞后期后,淋巴结和血液T细胞的消耗达到99%。这一过程与功能不匹配的恒河猴肾移植的生存期显著延长有关,在不进一步免疫抑制治疗的情况下,9个月内生存期延长50%。排异反应发生在抗移植物抗体出现之前(由S. Knechtle和J. Thomas完成)。为了避免这种不良的T细胞介导的B细胞反应,显然是在免疫毒素诱导的T细胞杀伤延迟期间启动的,我们添加了一种短疗程的药物,被认为可以阻断抗原呈递,如脱氧果苷(DSG)。5例双侧肾切除受者中,3例长期耐受,无进一步免疫抑制,移植物存活时间为4年或更长。在没有外源性胰岛素的情况下,通过将非空腹血糖和糖化血红蛋白值恢复到正常水平来判断,同源胰岛细胞移植在患有自发性胰岛素依赖型糖尿病的猴子身上已被证明可以逆转糖尿病。短期疗程的免疫毒素、甲基强的松龙和环孢素可诱导胰岛产生稳定的操作耐受性,其中一例持续了一年多。这是首次报道的使用不依赖于慢性免疫抑制的耐受性方案的糖尿病逆转,这一过程先前被证明会损害移植胰岛功能(与J. Thomas合作完成)。通过使用抗t细胞免疫毒素联合14天的DSG和异体胰岛移植,链脲佐菌素诱导的猴子糖尿病已经成功逆转(与J. Thomas合作完成)。7人中有3人是长期耐受的幸存者(6-7年)。一种重组二价抗人抗t细胞免疫毒素已经被开发出来,其效力是以前化学偶联物的20倍。这在毕赤酵母中表现出来。这种材料现在已经用于T细胞白血病的I期临床试验,并且已经提交了INDA。为了帮助毕赤酵母产生免疫毒素和其他生物活性蛋白,已经构建了新的菌株,在活性未折叠蛋白反应存在的情况下,表现出毒素抗性和增加外源蛋白产量。
项目成果
期刊论文数量(20)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice.
人 CD3ε 转基因小鼠中抗人 CD3 免疫毒素诱导 T 细胞耗竭和移植物存活。
- DOI:10.1097/00007890-200205270-00023
- 发表时间:2002
- 期刊:
- 影响因子:6.2
- 作者:Weetall,Marla;Digan,MaryEllen;Hugo,Ronald;Mathew,Sheba;Hopf,Christine;Tart-Risher,Nicole;Zhang,Jin;Shi,Victor;Fu,Fumin;Hammond-McKibben,Denise;West,Susan;Brack,Richard;Brinkmann,Volker;Bergman,Reinhard;NevilleJr,David;Lake,
- 通讯作者:Lake,
Chimeric fusion proteins--diphtheria toxin-based.
嵌合融合蛋白——基于白喉毒素。
- DOI:
- 发表时间:2001
- 期刊:
- 影响因子:0
- 作者:Frankel,AE;Powell,BL;Vallera,DA;NevilleJr,DM
- 通讯作者:NevilleJr,DM
Effects of xenogeneic thymic transplantation in baboons.
异种胸腺移植对狒狒的影响。
- DOI:10.1016/s0041-1345(00)02244-2
- 发表时间:2001
- 期刊:
- 影响因子:0.9
- 作者:Wu,A;Yamada,K;Awwad,M;Kitamura,H;Wain,J;Neville,DM;Cooper,DK;Sykes,M;Sachs,DH
- 通讯作者:Sachs,DH
Xenogeneic thymus transplantation in a pig-to-baboon model.
猪狒狒模型中的异种胸腺移植。
- DOI:10.1097/01.tp.0000044137.97841.99
- 发表时间:2003
- 期刊:
- 影响因子:6.2
- 作者:Wu,Anette;Yamada,Kazuhiko;Neville,DavidM;Awwad,Michel;Wain,JohnC;Shimizu,Akira;Gojo,Satoshi;Kitamura,Hiroshi;Colvin,RobertB;Cooper,DavidKC;Sykes,Megan;Sachs,DavidH
- 通讯作者:Sachs,DavidH
Minimization of aggregation of secreted bivalent anti-human T cell immunotoxin in Pichia pastoris bioreactor culture by optimizing culture conditions for protein secretion.
通过优化蛋白质分泌的培养条件,最大限度地减少毕赤酵母生物反应器培养中分泌的二价抗人 T 细胞免疫毒素的聚集。
- DOI:10.1016/j.jbiotec.2005.07.004
- 发表时间:2006
- 期刊:
- 影响因子:4.1
- 作者:Woo,JungHee;Liu,YuanYi;NevilleJr,DavidM
- 通讯作者:NevilleJr,DavidM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Neville其他文献
Proteines de fusion d'immunotoxines et leurs moyens d'expression
免疫毒素融合蛋白和表达途径
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:0
- 作者:
David M. Neville;Jerry T. Thompson;Huaizhong Hu;Jung;Shenglin Ma;J. M. Hexham;Mary Ellen Digan - 通讯作者:
Mary Ellen Digan
Insulin Action in Isolated Rat Thymocytes: I. BINDING OF <sup>125</sup>I-INSULIN AND STIMULATION OF α-AMINOISOBUTYRIC ACID TRANSPORT
- DOI:
10.1016/s0021-9258(19)44673-5 - 发表时间:
1972-11-01 - 期刊:
- 影响因子:
- 作者:
Ira D. Goldfine;Jerry D. Gardner;David M. Neville - 通讯作者:
David M. Neville
Receptors for polypeptide hormones: Direct studies of insulin binding to purified liver plasma membranes
- DOI:
10.1007/bf02615997 - 发表时间:
1974-05-01 - 期刊:
- 影响因子:1.900
- 作者:
David M. Neville - 通讯作者:
David M. Neville
Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine1
小型猪对跨主要组织相容性障碍的复合组织同种异体移植物的耐受性1
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:6.2
- 作者:
S. Hettiaratchy;E. Melendy;Mark A. Randolph;Rebecca C. Coburn;David M. Neville;D. H. Sachs;Christene A. Huang;W. P. A. Lee - 通讯作者:
W. P. A. Lee
γ‐Glutamyltransferase in kidney brush border membranes
肾刷状缘膜中的γ-谷氨酰转移酶
- DOI:
- 发表时间:
1972 - 期刊:
- 影响因子:0
- 作者:
Hartmut Glossmann;David M. Neville - 通讯作者:
David M. Neville
David M. Neville的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Neville', 18)}}的其他基金
Tolerance In Organ Transplantation And Autoimmune Diseas
器官移植和自身免疫性疾病的耐受性
- 批准号:
6823951 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Tolerance In Organ Transplantation And Autoimmune Diseas
器官移植和自身免疫性疾病的耐受性
- 批准号:
7312867 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
TOLERANCE IN ORGAN TRANSPLANTATION AND AUTOIMMUNE DISEASE BY T CELL IMMUNOTOXIN
T 细胞免疫毒素对器官移植和自身免疫性疾病的耐受性
- 批准号:
6432850 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Tolerance In Organ Transplantation And Autoimmune Diseas
器官移植和自身免疫性疾病的耐受性
- 批准号:
6671607 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Treatment of childhood regresive autism with minocycline.
用米诺环素治疗儿童回归自闭症。
- 批准号:
7594593 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Tolerance In Organ Transplantation & Autoimmune Disease
器官移植的耐受性
- 批准号:
7136268 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Treatment of childhood regresive autism with minocycline
米诺环素治疗儿童回归自闭症
- 批准号:
7312936 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
TOLERANCE IN ORGAN TRANSPLANTATION AND AUTOIMMUNE DISEASE BY T CELL IMMUNOTOXIN
T 细胞免疫毒素对器官移植和自身免疫性疾病的耐受性
- 批准号:
6111217 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
TOLERANCE IN ORGAN TRANSPLANTATION AND AUTOIMMUNE DISEASE BY T CELL IMMUNOTOXIN
T 细胞免疫毒素对器官移植和自身免疫性疾病的耐受性
- 批准号:
6290587 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
Tolerance In Organ Transplantation And Autoimmune Diseas
器官移植和自身免疫性疾病的耐受性
- 批准号:
6541860 - 财政年份:
- 资助金额:
$ 113.17万 - 项目类别:
相似海外基金
Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
- 批准号:
26462277 - 财政年份:2014
- 资助金额:
$ 113.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
- 批准号:
8344380 - 财政年份:2012
- 资助金额:
$ 113.17万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7878675 - 财政年份:2009
- 资助金额:
$ 113.17万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7677758 - 财政年份:2009
- 资助金额:
$ 113.17万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7466112 - 财政年份:2008
- 资助金额:
$ 113.17万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8010394 - 财政年份:2008
- 资助金额:
$ 113.17万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8208131 - 财政年份:2008
- 资助金额:
$ 113.17万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7575273 - 财政年份:2008
- 资助金额:
$ 113.17万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7765518 - 财政年份:2008
- 资助金额:
$ 113.17万 - 项目类别: